ALS Treatment- We Still Await the "Magic Cocktail"
- PMID: 36211158
- PMCID: PMC9540951
- DOI: 10.4103/aian.aian_397_22
ALS Treatment- We Still Await the "Magic Cocktail"
References
-
- Watanabe T, Yuki S, Egawa M, Nishi H. Protective effects of MCI-186 on cerebral ischemia: Possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther. 1994;268:1597–604. - PubMed
-
- Ito H, Wate R, Zhang J, Ohnishi S, Kaneko S, Ito H, et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol. 2008;213:448–55. - PubMed
-
- Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–12. - PubMed
-
- Hardiman O, van den Berg LH. Edaravone: A new treatment for ALS on the horizon. Lancet Neurol. 2017;16:490–1. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous